Introduction: Coronavirus disease 2019 (COVID-19) is characterised by a pro-coagulant state that can lead to thromboembolic events. A high prevalence of Lupus Anti-coagulant has been shown in several studies, that may atleast partially explain the procoagulant prole of COVID-19. Few people infected by Coronavirus have become seriously ill while others showed little or no signs or symptoms related to COVID-19. This study was undertaken to analyze Haematological, Immunohaematological parameters and clinical Chemistry prole among LA positive and LA negative COVID -19 cases. Objectives: 1. To assess clinical, hematological and coagulation prole in COVID-19 lupus anticoagulant positive cases and lupus anticoagulant negative cases .. 2. To correlate ndings amongst lupus anticoagulant positive and negative cases. 3. To assess inammatory status amongst Covid-19 lupus anticoagulant positive and negative cases with markers like Crp-q, LDH, D-Dimer and Ferritin. Materials and Methods: The study was conducted as a prospective observational study with search data forms from the case records of patients hospitalized as ICU/ non- ICU COVID-19 cases in MGM Hospital and Medical College, Aurangabad during the pandemic for a total duration of 2 years from December 2020 to December 2022. A total of 90 patients with conrmed diagnosis of COVID-19 by RTPCR/RAT were studied. To assess Lupus Anti-Coagulant positivity- Dilute Russel Viper venom time (DRVVT) technique is used for established COVID-19 cases Conclusion: In conclusion, the current study conrmed no statistical correlation for parameters such as age, gender, comorbidities (hypertension, diabetes mellitus, COPD, IHD) in LA positive and LA negative cases. There was no statistical correlation found for ANA, RA factor, Inammatory markers and Coagulation prole among LA positive and LA negative cases. Neutrophil : Lymphocyte ratio and Lymphocyte : CRP ratio did not statistically differ in LA positive and LA negative cases. Complications (stroke, IC bleed, DVT, PTE) were observed in 16.27% LA negative patients while none of the above complications were seen in LA positive patients. Further large scale studies are required to comment on differences in Haematological, Immunohaematological and Clinical Chemistry prole between LA positive and LA negative cases.